Abstract
Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors.
Highlights
EXPRESSION OF CONCERN- In Figure 3, similarities were noted between the p-MAPK44/42 and pMEK blots for HCT116 cells
After publication of this article [1], the following concerns were raised about results reported in Figures 1, 3, 5, and 6:
- In Figure 3, similarities were noted between the p-MAPK44/42 and pMEK blots for HCT116 cells
Summary
- In Figure 3, similarities were noted between the p-MAPK44/42 and pMEK blots for HCT116 cells. - In Figure 3, similarities were noted between the p445-BRAF and pMEK blots for CALU-3 cells. The authors replicated the experiments for which concerns were raised using the same methods and conditions as in the original study [1]. The PLOS ONE Editors issue this Expression of Concern to notify readers of the issues raised for the published figures and the unavailability of original data for this study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have